Phase Ia Study of ChAd63/MVA PvDBP

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
MalariaPlasmodium Vivax
Interventions
BIOLOGICAL

ChAd63 PvDBP 5 x 10^9

1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly

BIOLOGICAL

ChAd63 PvDBP 5 x 10^10

1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

BIOLOGICAL

MVA PvDBP 1 x 10^8

1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly

BIOLOGICAL

MVA PvDBP 2 x 10^8

1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01816113 - Phase Ia Study of ChAd63/MVA PvDBP | Biotech Hunter | Biotech Hunter